EternaTear Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$5.06M
- Investors
-
14
EternaTear General Information
Description
Developer of over-the-counter artificial tears designed to provide lasting relief to dry eyes. The company's artificial tear provides ocular lubrication and treats progressive dry eye by binding the tear film layers together to restore homeostasis in the eye, enabling patients to get relief from a painful and often debilitating dry eye condition.
Contact Information
Website
www.eternatear.comCorporate Office
- 700 Spring Forest Road
- Suite 127
- Raleigh, NC 27609
- United States
Corporate Office
- 700 Spring Forest Road
- Suite 127
- Raleigh, NC 27609
- United States
EternaTear Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series A) | 01-Oct-2020 | $5.06M | Completed | Startup |
EternaTear Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
EternaTear Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
EternaTear Patents
EternaTear Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4489783-A1 | Ophthalmic formulations and related methods | Pending | 08-Mar-2022 | ||
| EP-4489783-A4 | Ophthalmic formulations and related methods | Pending | 08-Mar-2022 | ||
| JP-2025509391-A | Ophthalmic formulations and related methods | Pending | 08-Mar-2022 | ||
| US-11679078-B1 | Ophthalmic formulations and related methods | Active | 08-Mar-2022 | ||
| US-11679079-B1 | Ophthalmic formulations and related methods | Active | 08-Mar-2022 | A61K9/0048 |
EternaTear Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
EternaTear Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ariel Savannah Angel Partners | Angel Group | Minority | ||
| Band of Angels | Angel Group | Minority | ||
| Beldon Global | Impact Investing | Minority | ||
| Carolina Angel Network | Angel Group | Minority | ||
| CED Ventures | Venture Capital | Minority |
EternaTear FAQs
-
When was EternaTear founded?
EternaTear was founded in 2018.
-
Where is EternaTear headquartered?
EternaTear is headquartered in Raleigh, NC.
-
What is the size of EternaTear?
EternaTear has 2 total employees.
-
What industry is EternaTear in?
EternaTear’s primary industry is Pharmaceuticals.
-
Is EternaTear a private or public company?
EternaTear is a Private company.
-
What is the current valuation of EternaTear?
The current valuation of EternaTear is .
-
What is EternaTear’s current revenue?
The current revenue for EternaTear is .
-
How much funding has EternaTear raised over time?
EternaTear has raised $5.06M.
-
Who are EternaTear’s investors?
Ariel Savannah Angel Partners, Band of Angels, Beldon Global, Carolina Angel Network, and CED Ventures are 5 of 14 investors who have invested in EternaTear.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
